ApoE functions in plasma lipoprotein metabolism through its interaction with cell surface receptors such as LDL receptor (1-5) and apoE receptor (LDL receptor related protein) (6, 7). Recently, we and others demonstrated a reduction in plasma cholesterol levels after intravenous administration of apoE into WHHL rabbits (8, 9). Exogenous apoE was incorporated into plasma lipoproteins including very low density lipoproteins (VLDL), then VLDL enriched in apoE was removed rapidly from the blood through mutant LDL receptor or apoE receptor in WHHL rabbits, and induced the reduction in plasma cholesterol levels. This function of apoE is supposed to reduce the rate of atherogenesis because many studies have proved the relationship between plasma cholesterol level and the incidence of coronary heart disease (10, 11).
Many studies have suggested important roles of apoE in lipid transport in various tissues including liver, brain, peripheral nerves and arterial walls as well as in plasma (3, 12-14). However, in vivo effects of apoE are not fully understood.
To further investigate the role of apoE in lipoprotein metabolism and in atherogenic process, we attempted to produce transgenic mice which overexpress apoE in vivo (15).
Materials and Methods

Production of Transgenic Mice
Preparation of microinjected DNA fragment from pMAEII and production of the transgenic line, MAE 4-20 were as previously described (15). The highest expressor of apoE, line 4-20, was established.
Homozygotes for the transgene were obtained by mating three pairs of Fl animals and confirmed by comparing quantities of the integrated gene on Southern blot (15). Heterozygotes and nontransgenic littermates (12 weeks of age) were also used in the present study. To confirm the homozygocity for the transgene, one of six predicted female homozygotes was mated to a non-transgenic male mouse, and we found that the offspring were all positive for the integrated gene. To induce expression of the transgene, animals were given water containing 20 mM ZnS04 for one week. Fasting ester in aortae from animals treated with apoE as compared with those treated with saline (apoE : 1.55 mg/g aorta, saline : 4.32 mg/g aorta, Table 2 ). The accumulation of cholesterol ester in each segment of aorta was significantly less in animals treated with apoE than those with saline (p <0.001, Table 2 ). Supporting these observations, the lesion area with atherosclerotic plaque in the apoE group was much smaller than that in the salinegroup (18.8% vs. 38.8%, p < 0.002). portion (10 ,u I) of pooled fasting plasma sample from each group after the zinc treatment was applied to high performance liquid chromatography system composed of TSK G3000SW (Tosoh Co, Tokyo) and Superose 6HR (Pharmacia) as described in Materials and Methods. The peak positions of VLDL, LDL and HDL are indicated. The cholesterol levels (mg/di) in VLDL and LDL calculated from the plasma total cholesterol and from the curve area in the elution pattern of HPLC were as follows. VLDL cholesterol : control 9.5, homozygotes 0.3, LDL cholesterol : control 17.2, homozygotes 2.7. In the triglycerides monitoring in heterozygotes, the elution curves before (dotted line) and after (solid line) the zinc treatment are shown.
Discussion
Overexpression of apoE in transgenic mice caused dramatic changes in plasma lipids and lipoprotein profile. The effects of overexpressed apoE on plasma lipoprotein lipid levels were dose-dependent.
There were four stages of the plasma apoE levels in mice the level of controls, zinc-untreated heterozygotes (6 mg/dl, low expression), treated heterozygotes which is similar to that of untreated homozygotes (10 mg/dl, middle expression), and treated homozygotes (17 mg/dl, high expression). A decrease in plasma cholesterol level was observed at the plasma apoE level of middle expression.
It is consistent with the data reported by Smith et al. that no significant changes in plasma cholesterol levels were found in the transgenic mice with the level of 3-4 mg/dl of human apoE corresponding to our low expression level (18). Decreases in plasma VLDL-and LDL-cholesterol levels were already observed at the plasma apoE level of low expression, and the greater plasma apoE level, the more prominent decreases in plasma VLDL-and LDLcholesterol levels were observed. In the same plasma apoE level, decreases in plasma triglycerides were much more remarkable than those in plasma cholesterol. Plasma VLDL triglycerides were remarkably reduced even at the plasma apoE level of low expression and were eliminated at both levels of middle and high expression. Supporting the significant reduction in plasma lipoprotein lipids in transgenic mice, marked reduction in plasma apoB levels of treated homozygotes was observed, which indicates the elimination of most of lipoproteins containing apoB. These data suggested that apoE has the most profound effect on the metabolism of triglycerides rich lipoproteins such as VLDL, and the least remarkable in HDL. VLDL particles, which are synthesized in the liver, can be associated with overexpressed apoE in the liver, achieve a high affinity for LDL receptor, resulting in a rapid plasma clearance of VLDL through receptormediated pathways (2, 4, 5, 8, 9, 19-21). The reduction in LDL cholesterol could be caused by a reduced production in a metabolic cascade from VLDL of which clearance was enhanced.
Possibly, additional apoE might also enhance the clearance of LDL particles.
In the present study, we demonstrated that apoE is an essential apolipoprotein which determines the level and profile of lipoproteins, especially lipoproteins containing apoB, by influencing the interaction between lipoprotein receptors and lipoproteins.
One of the best ways to evaluate the effects of agents that can affect the rate of atherogenesis in vivo is longterm administration of such agents to young WHHL rabbits which have not yet developed atherosclerotic lesions (22, 23) . In the present study, we injected a relatively low dose of apoE (10 mg/animal/day) into young WHHL rabbits (2.5 months) as compared to the previous study, to minimize the effects of apo E on plasma cholesterol levels (24). During the experimental period, there were no significant differences in plasma lipid levels between the two groups. ApoE definitely reduced the rate of atherogenesis after 8.5 month-treatment in WHHL rabbits. The cholesterol accumulation and lesion area were reduced approximately 1/3 and 1/2, respectively, in animals treated with apoE as compared to those with saline. Similar retarded progression of atherosclerosis without significant change in plasma cholesterol level was demonstrated only in WHHL rabbits given probucol (23).
ApoE secreted from peripheral tissues such as macrophages is suggested to be involved in cholesterol transport from peripheral tissue to liver, which is called a reverse cholesterol transport system (3, 25, 26). Cholesterol-loaded cells such as macrophages release their cholesterol to either HDL or other acceptor proteins including apoE and apo Al in the interstitial fluid. In vitro studies showed that the presence of apoE facilitates the acquisition of cholesterol by HDL (25), and apoE itself actively accepts cholesterol from cholesterol-loaded cells (27). HDL with apoE or apoE-lipid complex, after accepting cellular cholesterol, can bind to hepatic receptors including LDL receptors and apoE receptors by virtue of the presence of apoE on lipoproteins.
Thus, the extracholesterol accumulating in the subendothelial foam cells can be transported with apoE to the liver, where it is removed by receptor-mediated endocytosis. In addition to the effects of apoE on lipoprotein metabolism, apoE influences the functions of lymphocytes and smooth muscle cells, which are major cell components of arterial walls (3, 28). It is possible that cellular functions influenced by the presence of apoE play important roles in reducing the rate of atherogenesis in WHHL rabbits. In the present study, we demonstrated that apoE prevents the progression of atherosclerosis in WHHL rabbits . Although the precise mechanism of apoE action in the prevention of atherosclerosis is yet unknown, exogenous apoE may influence the rate of atherogenesis by not only activating the reverse cholesterol transport system but also modifying cellular functions in the arterial wall, rather than by enhancing the cholesterol accumulation in the arterial wall. 
